117 related articles for article (PubMed ID: 22370312)
1. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.
Alvarez-Twose I; González P; Morgado JM; Jara-Acevedo M; Sánchez-Muñoz L; Matito A; Mollejo M; Orfao A; Escribano L
J Clin Oncol; 2012 Apr; 30(12):e126-9. PubMed ID: 22370312
[No Abstract] [Full Text] [Related]
2. Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.
Jung AG; Horny HP; Sotlar K; Overbeck T; Schön MP; Lippert U
J Am Acad Dermatol; 2011 Jul; 65(1):224-6. PubMed ID: 21679828
[No Abstract] [Full Text] [Related]
3. Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Carella AM
Leuk Res; 2004 Apr; 28(4):421-2. PubMed ID: 15109544
[No Abstract] [Full Text] [Related]
4. Imatinib for systemic mast-cell disease.
Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation.
Dalal BI; Horsman DE; Bruyèrè H; Forrest DL
Am J Hematol; 2007 Jan; 82(1):77-9. PubMed ID: 17133421
[No Abstract] [Full Text] [Related]
6. Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
Chan CY; Browning J; Smith-Zagone MJ; Martinelli PT; Hsu S
Dermatol Online J; 2007 May; 13(2):29. PubMed ID: 17498448
[No Abstract] [Full Text] [Related]
7. Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis.
Elliott MA; Pardanani A; Li CY; Tefferi A
Leukemia; 2004 May; 18(5):1027-9. PubMed ID: 15014525
[No Abstract] [Full Text] [Related]
8. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
9. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
[TBL] [Abstract][Full Text] [Related]
10. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
[TBL] [Abstract][Full Text] [Related]
11. Systemic Mastocytosis: documented pathologic response to imatinib.
Gollard RP; Ruemmler-Fish C; Garcia D
Eur J Haematol; 2007 Oct; 79(4):367-8. PubMed ID: 17655701
[No Abstract] [Full Text] [Related]
12. Not all c-kit mutations can be corrected by imatinib.
Lasota J
Lab Invest; 2007 Apr; 87(4):317. PubMed ID: 17486696
[No Abstract] [Full Text] [Related]
13. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.
Merante S; Chichino G; Boveri E; Gottardi E; Soverini S; Cilloni D; Martinelli G
J Clin Oncol; 2006 Feb; 24(4):e6-7. PubMed ID: 16446324
[No Abstract] [Full Text] [Related]
14. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
15. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
16. Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13).
Shin J; Kim M; Kim DB; Yeom JO; Lee HJ; Cho SG
Acta Haematol; 2008; 119(1):57-9. PubMed ID: 18268406
[No Abstract] [Full Text] [Related]
17. Two cases of complete response after imatinib mesylate treatment of advanced GIST.
Papaxoinis G; Nikolaou M; Lianos E; Gaglia A; Economopoulos T; Pectasides D
Anticancer Res; 2006; 26(6C):4869-72. PubMed ID: 17214353
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial.
Chugh R; Wathen JK; Patel SR; Maki RG; Meyers PA; Schuetze SM; Priebat DA; Thomas DG; Jacobson JA; Samuels BL; Benjamin RS; Baker LH;
Clin Cancer Res; 2010 Oct; 16(19):4884-91. PubMed ID: 20724445
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
20. Papular-purpuric "gloves and socks" syndrome in systemic mastocytosis treated with imatinib: a diagnostic challenge.
Jaworek AK; Sacha T; Woźniak-Knop M; Hałubiec P; Giza A; Wojas-Pelc A
Pol Arch Intern Med; 2024 Jun; 134(6):. PubMed ID: 38640058
[No Abstract] [Full Text] [Related]
[Next] [New Search]
